Bluebird Bio Sold for $30 Million Amidst Financial Woes
Tap title to read story
Bluebird Bio, once a promising biotech firm, is being sold to Carlyle and SK Capital for approximately $30 million. The sale follows years of financial struggles, stemming from setbacks including safety concerns, pricing challenges in Europe, and slow sales of its gene therapies despite FDA approvals. Shareholders will receive $3 per share, with a potential additional $6.84 contingent on future sales. This marks a dramatic fall from a previous market cap of around $9 billion, highlighting the challenges faced by gene therapy companies in translating scientific breakthroughs into sustainable businesses.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.












